广东暨德康民

Guangdong Jide Kangmin Biotechnology is a clinical-stage biotechnology company focused on the research and development of next-generation immune cell therapies. Headquartered in Guangzhou, China, the company was established through the translation of scientific achievements from Jinan University. Jide Kangmin's core expertise lies in the design and manufacturing of Chimeric Antigen Receptor T-cell (CAR-T) and Natural Killer (NK) cell therapies, with a particular emphasis on multi-target and universal cell products. Their pipeline targets a range of conditions, including hematological malignancies like leukemia and lymphoma, as well as solid tumors such as liver cancer. The company aims to improve the efficacy and safety of cell therapies while reducing production costs to benefit a broader patient population.